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Objective. To explore evidence for the traditional Tibetan medicine, Zhi Byed 11 (ZB11), for use as a uterotonic. Methods.
The eleven ingredients in ZB11 were chemically analyzed by mass spectroscopy. A review was conducted of Western allopathic
literature for scientific studies on ZB11’s individual components. Literature from Tibetan and other traditional paradigms were
reviewed. Results. Potential mechanisms of action for ZB11 as a uterotonic include laxative effects, a dose-dependant increase in
smooth muscle tissue peristalsis that may also affect the uterus smooth muscle, and chemical components that are prostaglandin
precursors and/or increase prostaglandin synthesis. A recent RCT demonstrated comparable efficacy to misoprostol in reducing
severe postpartum hemorrhage (PPH) (>1000mL) and greater effect than placebo. Historical and anecdotal evidence for ZB11 and
its ingredients for childbirth provide further support. Discussion. ZB11 and its ingredients are candidates for potentially effective
uterotonics, especially in low-resource settings. Further research is warranted to understand the mechanisms of action and synergy
between ingredients.
1. Introduction
1.1. Uterotonics for Prevention of Postpartum Hemorrhage
(PPH). PPH is a leading cause of maternal morbidity and
mortality worldwide. It is estimated that of the approxi-
mately 350,000 women who die annually from complications
of pregnancy and childbirth, more than 25% die of obstetric
hemorrhage [1]. This burden is unequally held by developing
countries, where it occurs at a rate 100 times higher than
in the developed world [2]. One key factor is that many
women deliver at home without skilled delivery attendance,
where complications often go unrecognized and untreated.
By the time a problem is identified and the woman is trans-
ported to an appropriate facility, it may be too late. Women
can deteriorate so rapidly that even if they arrive at an ap-
propriate medical facility alive, they may already be in irre-
versible shock and/or have developed disseminated intravas-
cular coagulopathy (DIC) [3].
The third stage of labor is the time period between
the birth of the infant and delivery of the placenta and
2 Evidence-Based Complementary and Alternative Medicine
membranes. Failure or delay of the uterus to appropriately
contract after delivery can lead to rapid and massive hemor-
rhage. Shortening the third stage of labor and ensuring that
the uterus is well contracted during this time has the poten-
tial to decrease blood loss and the incidence of hemorrhage.
The World Health Organization (WHO), the International
Federation of Gynecology and Obstetrics (FIGO), and the
International Confederation of Midwives (ICM) advocate
the use of a uterotonic to decrease postpartum bleeding by
up to 50%–70% [4].
A uterotonic is a substance that increases the tone
(causes contraction) of the uterus, an organ composed of
smooth muscle tissue. In both allopathic and traditional and
herbal medicine, substances that are called uterotonics often
have laxative, purgative, diarrheagenic, cathartic, abortifa-
cient, and emmenagoguic effects. Some uterotonics are bi-
ochemically synthesized hormones, such as oxytocin, that
act on distant hormone receptors or upstream from other
hormones in the body to induce uterine contractions. Others
may be synthetic prostaglandins or prostaglandin precursors.
Prostaglandins are lipid compounds derived enzymatically
from fatty acids and serve as locally acting messenger mol-
ecules performing important functions in the body such as
regulating the contraction and relaxation of smooth muscle
[5].
Since 2007, the WHO PPH Prevention Guidelines have
stated that the uterotonic of choice for prophylaxis of PPH
is 10 IU of oxytocin delivered intramuscularly [6]. Oxytocin
(pitocin and syntocinon) is a hormone produced in the hy-
pothalamus that plays a critical role in labor and delivery
by stimulating uterine contraction, and in lactation by caus-
ing milk letdown. However, there are barriers to its use in
low-resource settings. To maintain the highest potency, oxy-
tocin requires refrigeration. It is only effective if given par-
enterally [4], thus safe administration of oxytocin requires
staff trained in intravenous or intramuscular administration
techniques, sterile needles, and safe disposal for injection
equipment. These are frequently unavailable or too costly
during births in low-resource settings. The uterotonic er-
gometrine has similar efficacy to oxytocin but has more
side effects, which makes it the preferred option only when
oxytocin is not available [6]. Like oxytocin, its utility in low-
resource settings is lessened by special storage requirements
and parenteral administration [7].
The uterotonic misoprostol has been recommended as an
alternative to oxytocin and ergometrine for the prevention of
PPH in low-resource settings, primarily due to its greater ease
of administration and storage [8]. Misoprostol (Cytotec) is
a synthetic prostaglandin E1 analogue that has been shown
to significantly decrease PPH when compared to placebo [9,
10]. Unlike oxytocin, misoprostol can be taken orally and is
also relatively stable; it can be stored at room temperature
in a closed container safe from humidity with a shelf life of
several years [11].
Misoprostol has drawbacks, most notably side effects
including pyrexia, nausea, shivering, and diarrhea. Studies
of 600mcg of misoprostol have shown pyrexia and shivering
to be most common, with 4%–38% reporting pyrexia and
32%–57% reporting shivering [7, 9, 10]. These findings are
dose dependant; malignant hyperpyrexia has been reported
at 800mcg orally [10, 12], with potentially dangerous
outcomes such as uterine rupture, abruption, fetal demise,
and maternal death if used inappropriately during the active
phase of labor at doses above 50mcg [13, 14]. Another bar-
rier is that misoprostol is not approved for obstetric or gy-
necologic indications in many countries [15], and thus may
not be widely available. Where use is restricted because of
concerns for its use as an abortifacient, it may only be found
on the black market, causing concern for its purity and
safety. Due to misoprostol’s side effects and inconsistent out-
comes across studies [16], the search for an alternative oral
uterotonic for low-resource settings continues.
The ideal uterotonic for prevention of PPH at the home
or community level is one that is simultaneously efficacious,
affordable, widely available, does not require electricity or
technology for effective storage, has a low side effect profile
and high safety level, and is compatible with local beliefs and
traditional practices. There may be alternatives to current
allopathic medicines within traditional medical systems that
would fit these ideals for the prevention of PPH.
Since at least 1500 BC traditional medical practices have
taken advantage of the uterotonic properties of local herbs
to promote uterine contractions and/or control PPH. These
systems include but are not limited to US-based midwifery,
African traditional, Ayruveda, Chinese traditional, and Ti-
betan medicine. The history of ergometrine is an example
of how a naturally occurring substance was discovered to be
a uterotonic and became widely used in Western allopathic
medicine. Ergometrine is derived from the naturally occur-
ring substance ergot, the alkaloid-containing product of the
fungus,Claviceps purpurea, which grows on grain. References
to ergot date as far back as 600 BC, and its effects on preg-
nancy were identified in the 16th century by midwives who
noted an increased rate of miscarriage during epidemics of
“ergotism”, a disease caused by eating contaminated rye
bread [17]. In 1935, the active substance was identified and
named ergometrine, effectively initiating the modern era of
allopathic uterotonics [18, 19].
In the USA, Chumash Native American communities in
California have used Trichostema lanatum and lanceolatum
leaves in a decoction to pass the afterbirth (placenta) [20].
Midwives frequently use herbal preparations that are pur-
ported to increase uterine tone (red raspberry leaf), act as
an emmenagogue to provoke menstruation (penny royal), or
induce labor contractions (blue cohosh, black cohosh, and
castor oil) [21]. Among South African native populations,
the Xhosa, Zulu, and Sotho tribes use over 57 traditional
herbal medicines during pregnancy and childbirth [22],
which have exhibited direct smooth muscle activity on the
uterus and/or ileum in vitro [23]. In Ayurvedic medicine, the
gentle anthraquinone-containing laxative Aragvadha, Cassia
fistula-Fructus, is used in pregnancy to stop bleeding and
cause a general “downward” movement. Rhubarb root is ad-
ministered internally to treat many forms of hemorrhage
[24]. In traditional Chinese medicine, (TCM), Motherwort,
or Leonurus heterophyllus sweet is considered the key ingre-
dient for PPH prescriptions and has been developed into
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an injection for clinical use (personal communication with
Taxiang Wu, Chinese Cochrane Centre, December 10, 2009).
In the Tibetan Autonomous Region (TAR) of China, Zhi
Byed 11 (ZB11) has been the traditional treatment of choice
for PPH for over 700 years and continues to be widely used by
Tibetan traditional healers and providers. It is also prescribed
to aid and quicken delivery, increase uterine contractions,
deliver the placenta, and to manage other complications of
pregnancy such as hypertension and infection. Currently,
much cheaper than conventional uterotonics at USD 0.04 per
dose, ZB11 is also widely available in the TAR and has a high
degree of acceptability. Taken orally and not requiring any
special storage, ZB11 is practical for home and community
births. ZB11 seems to hold none of the barriers allopathic
uterotonics such as oxytocin, ergometrine, and misoprostol
do for use in the TAR, and continues to be used by Tibetan
traditional healers [25].
Phuntsog Wangmo, a traditional Tibetan healer, and the
cultural director and an instructor at the Shang Shung Insti-
tute of America, International Institute for Tibetan Stud-
ies, Conway,Mass, USA, shares her personal experience using
ZB11 in contemporary rural Tibet:
“Zhi Byed 11, we use this commonly, this is a
very good medicine, it helps to clean the uterus,
for example, it helps if something remains in the
uterus to make sure that it is expelled. When I
am working with someone in labor, I do several
things. I will try to make sure that the baby’s
head is down. . .. We give some nutrition (like
warm broth) if the person is strong enough. If
contractions are getting weak, or the patient
does not dilate, we give ZB11. We give one pill
orally. If nothing happens after 1.5 hours, we
can give another one. We are allowed to give
2-3 pills. Once the baby has come out, we give
warm oil treatment. We keep the mother warm
and give her nutritional food, warm broth or
soup. At the same time, we get the placenta, put
oil on the abdomen, and do gentle massage,
downward traction on placenta. If the placenta
does not come out or if some pieces remain
inside, we would give another ZB11. We watch
the bleeding, if it continues, we check the color
of the blood. If dark, we are not so worried, if
it is fresh, then we are worried. I worked in a
remote area, so I have to stay with them at their
house. If needed, I stay overnight. If I have to
leave, then I give a good dosage of Gur gum 8
and make sure no bleeding. I leave them with
3–5 pills of ZB11, and have them take 1 in the
morning for three days. The reason for this is
to clean the uterus and keep it healthy. I think
it works as a team between all the ingredients.
The contractions become stronger, more painful
when it is given. I use it in almost everyone,
but the amount varies, between 1 pill or many
pills. I was always able to get that medicine, the
ingredients are not that difficult to find. It is not
expensive and there are many good sources.”
Traditional Tibetan medical literature states that ZB11
owes both its efficacy for preventing and treating PPH, and
low rate of side effects, to a careful balance of eleven syner-
gistic natural ingredients (see Figure 1). Recently, ZB11 be-
came the first traditional uterotonic to be rigorously tested
against an allopathic uterotonic for PPH. In a double-blind,
randomized, controlled trial (RCT) conducted by Miller et
al. [25] in three maternity hospitals in Lhasa, TAR, delivering
women (n = 967) were randomly assigned to receive either
ZB11 or misoprostol [25].
As herbal products can differ depending what part of the
ingredient is used, the ratios, and the quality of the ingre-
dients, the Miller et al. [25] study used a single large batch
of ZB11 made at a local factory, the the Mentzikhang Tra-
ditional Tibetan Medicine Factory, in Lhasa, Tibet in May
2004. Employing only one factory and using one single batch
for the entirety of the study minimized this risk. Samples
of the study’s ZB11 product were retested for potency every
six months throughout the trial from August 2005 to March
2007 to confirm there was no degradation.
The study’s primary combined outcome, which included
incidence of PPH (blood loss ≥ 500mL) administration of
open label uterotonics, or maternal death, was found to be
lower among the misoprostol group (16.1% versus 21.8% for
ZB11; P = 0.02). The proportion of women who experienced
blood loss ≥ 500mL was also lower with misoprostol (12%
versus 17% ZB11). However, there were no significant dif-
ferences in the more clinically important indicators of PPH:
blood loss ≥ 1000mL, (2.1%, misoprostol versus 3.1%,
ZB11, P = 0.29), mean measured blood loss (304mL for
misoprostol versus 332mL for ZB11, P = 0.15) or median
measured blood loss (250mL versus 265mL for ZB11, P =
0.086). The length of the third stage of labor was also similar
(7.2min for misoprostol versus 6.9min for ZB11). Use of
additional uterotonics occurred in 16% of those given ZB11
and 13% of those given misoprostol. Side effects were more
common in the misoprostol group, with fever significantly
more common in the misoprostol group (2.7% versus 0.8%,
P = 0.03). There were no maternal deaths in either arm of the
study [25].
ZB11’s comparable results for several outcomes, long
history of use and acceptability in the TAR, strong anecdotal
support from Tibetan healers, low side effect profile, and the
pressing need to find a uterotonic appropriate for use in low-
resource settings prompted us to take a more detailed exam-
ination of ZB11. We were specifically interested in ZB11’s
individual ingredients and any known synergistic effects
between ingredients for possible mechanisms of action as
a uterotonic, their toxicology and safety profile in clinical
use, and historical and current uses, especially for purposes
related to childbirth.
2. Methods
In this paper, we explore the potential mechanisms of action
for ZB11 as a uterotonic, either as a combined preparation
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ZB11
Finished preparation
a ru
(Terminalla chehula Retz)
fruit with one seed 75 g
dig srin
(Potamon yuanense kemp)
flesh 25 g
bul tog
(Trona)
mineral 150 g
sga kya (Zingiber officinale
Rose; Hedychium spicatum)
root 50 g
ma nu (Inula racemosa
Hood; Inula helenium L)
root 25 g
cong zhi
mineral 125 g
star bu
(Hippophae rhamnoides L)
fruit with one seed 35 g
sbrul sha
(Zaocys dhumnades Cantor)
flesh 20 g
lcum rtsa
(Rheum palmatum L)
root 100 g
ol mo’se (Sinopodophyllum
hexandrum Royle)
fruit with many seeds 35 g
rgya tsha
(Sal ammoniacum)
mineral 15 g
(calcitum varieties)
Figure 1: Zhi Byed 11 ingredients by name, component, and weight.
or as a subset of its individual ingredients. The methodology
of this paper makes use of chemical analysis, evidence-based
review of both Western allopathic literature and peer
reviewed journals on traditional and herbal medicine, and a
review of Tibetan and other traditional and herbal medicine
paradigms.
The chemical makeup of the ZB11 used in the Miller
et al. [25] study was examined by mass spectroscopy at the
University of Utah Center for Human Toxicology [27]. These
findings were then cross-checked against those reported for
each ingredient in Mosby’s Handbook of Herbs and Natural
Supplements [28].
A literature search was conducted for each of ZB11’s
eleven ingredients. Databases used included PubMed, the
Cochrane Database of Systematic Reviews, and the CEN-
TRAL Controlled Trials Database. No parameters were set
for year, as many herbal medicines have a long history
and historical accounts may be considered valuable. The
terms entered were both the Latin name and the common
name of the individual ingredients found in ZB11. Articles
in English or those translated into English were examined.
We reviewed articles and selected those with relevance to
potential mechanisms of action on smooth muscle (as the
uterus is made up of smooth muscle), pregnancy, bleeding,
or uterotonic function. All animal and/or human studies that
used the pure ingredients were included. Information about
side effects and toxicity was also collected from this search.
The historical usage of ZB11 as a complex preparation of
eleven ingredients and of each individual ingredient was
explored by a review of texts on Tibetan traditional medicine,
traditional Chinese medicine, and herbal medicine.
3. Results
3.1. Chemical Analysis. The ZB11 used in the Miller et
al. [25] study was examined by mass spectrometry by
Andrenyhak [27], University of Utah Center for Human
Toxicology. This paper was created to test the ZB11 product
to be used in the Miller et al. [25] study. The primary
compounds identified included long chain fatty acids,
long chain fatty alcohols, and long chain methyl esters,
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Table 1: Zhi Byed 11 Tibetan, Latin, and common names, chemical components.
Tibetan name Latin name Common name Chemical component [25, 26]
a ru Terminalia chehula retz Chebulic myrobalan Ellagic acid, gallic acid, lufeoic acid, and chebulinic acid
bul tog Trona sodium, bicarbonate NaHCO3
cong zhi Calcitum calcium Calcium
lcum rtsa Rheum Palmatum L
Chinese, Turkish, or East
Indian rhubarb
Anthraquinones: rhein, chrysophanol, aloe
emodintannins gallo, galloy-1glucose stilbene,
phenolic, and polyketide synthase sennosides
ma nu
Inula Racemosa Hood,
Inula Helenium
elecampane
Volatile oil: alantolactone lactone: Alantol
polysaccharides: lnulin
ol mo’se
Sinopodophyllum
hexandrum (Royle)
Himalayan or Chinese
mayapple
Podophyllotoxin Picropodophyllin: Apha and beta
phyllin
rgya tsha Sal ammoniacum salt of sulphur/tar Na2S
sbrul sha Zaocys dhumnades Cantor black snake meat Not found
sdig srin Potamon ynnanense kemp freshwater crab shell Not found
sga skya
Zingiber offficinale Rose,
Hedychium Spicatum Ham
ginger, ginger Lily
Pungent gingerol, zingerone, Shogaol volatile oil,
bisabolene, zingiberene, zingiberol, and Sesquiterpene
star bu Hippophae rhamnoides L sea buckhorn
Anthranoid, emodin, anthraquinone glycosides,
frangulin A, B, glucofrangulin A, B
Table 2: Potential mechanisms of action of Zhi Byed 11.
Tibetan
namea
Mechanism of action
lcum
rtsa
Anthranoids: laxative due to direct colon irritation,
purgative potentially due to abnormal expression of
aquaporins [27].
Emodins: dose-dependant smooth muscle contraction
[28] due to increased concentration of calcium in
smooth muscle and the activation of calcium chloride
channels via enhancement of membrane Gi/Go protein
signal transducer pathway [29]. CaCl2 can reverse
effects. Heightens effects of Acetylcholine [28].
Sennosides: animal studies demonstrate intestinal
peristalsis due to depolarization of cell membranes,
quickened burst slow wave potential, and increased
frequency of spike potentials [30].
ma nu
Highly potent tracheal and ileal smooth muscle
relaxant in animal studies [30].
sga skya
Decreases nausea and vomiting [31] and prokinetic
activity in digestive system of animal models due to
effects on muscarinic M3 receptors of stomach fundus
[32].
star bu
Anthranoids: Laxative due to direct colon irritation
[19].
a
Studies on sbrul sha, ol mo’se, rgya tsha, a ru, bul tog, cong zhi, and sdig srin
are not found.
such as Eudesma (5,11 (13)-diene-8,12-olide), Physcion,
and Chrysophanol (9,10-Anthracenedione, 1,8-dihydroxy-3-
methyl) (see Table 1) [27].
3.2. Review of Western Allopathic Literature. Both RCTs and
animal models were found for four of the ZB11 ingredients
which suggested possible mechanisms of action for lcum
rtsa, star bu, and sga skya as uterotonics (see Table 2). These
include the laxative effects of anthranoids, smooth muscle
contractions of emodins (dose dependent), the peristaltic
effect of sennosides on the gastrointestinal system, and the
prokinetic and drug potentiating activity of sga skya (due
to its inhibition of first pass hepatic degradation). While no
studies looked specifically at the uterus for mechanism of
action, the effects on smooth muscle and the GI system is
relevant, since the uterus is also made up of smooth muscle.
Thus, often these mechanisms affect multiple organs with
smooth muscle and similar receptors, as evidenced by some
of the side effects experienced by the GI system when
allopathic uterotonics are used. Sga skya’s potentiatingmech-
anism would make any ingredient processed by the liver
more potent and/or act longer though we were not able to
find studies documenting whether the liver is responsible
for the metabolism and excretion of other ZB11 ingredients.
Conversely,ma nuwas found to have smoothmuscle relaxant
activity on the ileum and trachea; there was no study
documenting its effect on uterine smooth muscle.
Typical use of ZB11 is a short course (1–3 days) at
relatively low doses (1–3 pills.) In the Miller et al. [25] study,
all side effects, including diarrhea, shivering, and fever, were
more common in the misoprostol group than the ZB11
group, with fever being significantly higher (2.7% misopros-
tol versus 0.8% ZB11, P = 0.03). While this is a statistically
significant result, clinically, it may not be considered relevant.
Shivering was the most common side effect, occurring in
12% of participants given ZB11 and 16% of participants
given misoprostol. There were no life threatening adverse
events reported for ZB11 in this trial [25].
Other studies also describe side effects associated with
some ZB11 ingredients (see Table 3). It is important to note
that outside the Miller et al. [25] study, these reported side
effects were not accompanied by specific dosage levels or
schedules. The most serious side effects were reported only
anecdotally with unquantified long-term use or high doses
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Table 3: Zhi Byed 11 ingredient side effects and toxicities.
Tibetan
namea
Common side effects and toxicities [32, 33]
Side effects and toxicities in large doses/prolonged useb
[33]
cong zhi
Constipation, anorexia, nausea, vomiting, flatulence,
diarrhea, and rebound hyperacidity
None found
lcum rtsa Cramp like discomforts None found
ma nu
Irritate mucus membranes, sensitizing, and can cause
allergic contact dermatitis by forming haptens
Vomiting, diarrhea, cramps, and symptoms of paralysis
ol mo’se Nausea, vomiting, diarrhea, and abdominal pain
Seizures, stupor, coma, hepatotoxicity, leukopenia,
thrombocytopenia, anemia, and apnea
sga skya Nausea, vomiting, anorexia, and hypersensitivity reactions Arrhythmias
star bu
Nausea, vomiting, diarrhea, anorexia, abdominal cramps,
hepatotoxicity, dehydration, and nervousness/tremors
None found
a
sbrul sha, rgya tsha, a ru, bul tog, and sdig srin toxicity data are not found bexact dosage not stated, but reported as “large” or dosing “prolonged”.
Table 4: Uses of Zhi Byed 11 Individual Ingredients in Traditional
Tibetan Medicine.
a ru
Laxative [34], improves and gives positive body
energy, helpful for most diseases.
bul tog
Laxative, synergy with lcum rtsa; downward
expelling [34]
cong zhi
Prevents vomiting, treats constipation [35]
balances bul tog by absorbing carbonic acids
[34]; treats diarrhea caused by either virus or
indigestion; supports “bon” nutrition; helpful
for treating fever from the endocrine system
and for treating ulcers [36]
lcum rtsa Treats irregular menstruation [33]
ma nu
Induces sweat and treats fever [36]; downward
expelling functions [33]
ol mo’se
Thins coagulated blood, promotes normal
menses; promotes uterine contractions,
delivers baby, expels placenta, some consider
the most important ingredient in ZB11 [33].
Also used to cleanse other uterine disorders
[36]
rgya tsha
Promotes uterine contractions, dilates cervix
[33]; used to cleanse the whole body, ease urine
retention, and reduce wound infections
sbrul sha
Delivers baby, expels placenta [33]; and
dissolves clots [37]
sdig srin
Downward circulation, prevents cramping,
promotes uterine contractions, dilates cervix
[33]; eases urine retention and is useful for
various kidney disorder [37]
sga skya
Improves blood circulation and congestion,
prevents clots [33]
star bu
Downward expelling of blood, prevents blood
clots [34]; cools down fevers and provides pain
relief, prevents blood clots (mostly used for
women’s disorders or lung problems) [33]
and were not reported in any controlled trials or animal
models. [25, 33].
3.3. Review of Traditional and Herbal Medicine Literature.
There was strong historical and anecdotal evidence for the
use of ZB11 ingredients, not only in Tibetan medicine (see
Table 4) but also in other traditional medicines (see Table 5),
as diuretics, uterine, and other smooth muscle stimulants,
laxatives, and for side-effect management such as preventing
and treating nausea and vomiting in a range of disorders.
4. Discussion
Our analysis supports ZB11’s safety and effectiveness as a
uterotonic with the potential to decrease the risk of PPH,
particularly in low-resource settings, where current allo-
pathic uterotonics face significant barriers to use. ZB11 has
several qualities that make it an attractive uterotonic for
prevention and/or treatment of PPH at the home or com-
munity level in Tibet. With over 700 years of history, it is
widely culturally accepted by birthing women, Tibetan heal-
ers, and family members in Tibet. At the same time, it is
highly affordable (USD 0.04 per dose) widely available, does
not require electricity or technology for effective storage,
and requires minimal training for administration. Its safety
profile is similar to misoprostol, the current standard of care.
In places where access to a steady supply of “Western” med-
ication may be limited, this offers an important, less costly
alternative.
Several possible mechanisms of action were identified
for ZB11 as an uterotonic. These include a dose-dependant
increase in peristalsis of smooth muscle, which is the uterus
tissue type. Fatty acid esters, such as the linoleic acid, methyl
ester, and oleic acid methyl ester found in the mass spec-
trometry solution of ZB11, are prostaglandin precursors and
are involved in prostaglandin synthesis [45, 46]. Eudesma, or
Inula helenium, contains alantolactone, which is known to
have cathartic, or purgative properties (emmenagoguic, se-
cretagogue, secretolytic) [47]. 9,10-Anthracenedione, 1,8-
dihydroxy-3-methyl (also known as chrysophanol) and rhein
are both anthroquinones found in Chinese rhubarb species,
such as Rheum palmatum. Researchers at the Beijing Medical
University’s College of Pharmacology have conducted studies
on the chemical composition and bioactivities of dozens of
Rheum species and attribute many with purgative properties.
Rhein and chrysophanol are also found in the senna species,
known as a laxative [25, 33].
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Table 5: Relevant therapeutic uses of Zhi Byed 11 ingredients in other traditional systems.
Tibetan name∗
(common name)
Tradition/region of use Relevant therapeutic use within system/region
a ru Chebulic Myrobalan Ayurvedic/Indian
Improving gastrointestinal motility, laxative, purgative,
and cure for bleeding [38, 39]
bul tog Sodium,
bicarbonate
Africa Herbal Laxative [40]
lcum rtsa rhubarb
Traditional Chinese
Medicine
Purgative, laxative [41]; to treat hemorrhage [30, 32]
Ayurvedic To treat hemorrhage [19, 21]
ol mo’se Himalayan
mayapple
Traditional Chinese
Medicine
Emmenagogue, uterine stimulant, and abortifacient
[42]
sga skya ginger
Traditional Chinese
Medicine
Increases gastric secretions, increases intestinal
peristalsis [33]
Ayurvedic
Treating constipation, nonspecific antispasmodic effect
on smooth muscles [35, 43]
Unani (Indian Traditional
Greco-Arabic medicine)
Laxative [35]
East African Herbal
(Uganda)
Induction of uterine contractions [19]
star bu sea buckthorn
Traditional Asian Medicine
(Mongolia and China)
Constipation gynecological diseases [44]
∗
Information not found for cong zhi, ma nu, rgya tsha, sbrul sha or sdig srin.
In the Miller et al. [25] study, the sample size was cal-
culated using the assumption that the effect of ZB11 would
not be the same as placebo but would be at least a 10% de-
crease from hemorrhage occurrence when no treatment was
given. This assumption was validated in the study, where
there was a 15% decrease in PPH rates from baseline (be-
fore the initiation of any treatment.) This 15% decrease fur-
ther supports the uterotonic effect of ZB11. Notably, in the
same study, there was no significant difference between mis-
oprostol and ZB11 in blood loss ≥1000mL. This is striking
given that blood loss≥1000mL is considered one of the most
clinically meaningful indices of PPH, correlating with the
95th percentile for blood loss and greater associated mor-
bidity andmortality [48]. An uncomplicated vaginal delivery
often results in blood loss greater than 500mL. A change in
systolic blood pressure is not seen until 1000mL is lost, and a
blood loss of greater than 2000mL is necessary before systolic
blood pressure reaches levels as low as 50–70mmHg [49].
More research is warranted to determine the true effect of
ZB11 in preventing and/or treating PPH. Given that a pla-
cebo-controlled trial is unlikely due to ethical challenges, the
best option may be a double-blinded noninferiority trial of
ZB11 versus misoprostol, with the main outcome evaluating
the effect on severe hemorrhage (blood loss > 1000mL). We
also recommend that any future RCT follow the CONSORT
statement for herbal medicine RCTs [50].
Traditional Tibetan medicine is crafted for each patient
depending on many specific environmental and individual
factors. Scientifically, this is difficult to evaluate using a
“Western” approach. Similar to dosing trials in the pharma-
ceutical industry, different dosages and/or combinations of
ZB11 ingredients may alter the efficacy and/or side effects
of the medication. Evaluating different combinations of all
11 ingredients would require a large amount of resources
and time and still may not result in a “one size fits all” pill.
Therefore, capturing the true effect of ZB11 via standardized
scientific “Western” analysis may always be difficult. It may
be useful to conduct more qualitative work surrounding the
traditional proportions of ingredients that make up ZB11
and test a wide range of samples to identify the most com-
mon mixture though a challenge is that traditionally a mix-
ture is made specific to each patient. It may also be beneficial
to compare different formulations of ZB11 looking for a bal-
ance of efficacy and safety before beginning a trial.
The reported side effects in the Miller et al. [25] study of
diarrhea, shivering, and fever were lower for ZB11 than with
oral misoprostol though the clinical significance of the differ-
ence is unclear. If a medication has a high side-effect profile,
medical personnel may be reluctant to administer the medi-
cation; women themselves may refuse to receive it in subse-
quent deliveries or may tell friends and family to avoid the
medication and/or the facility where it is administered. Sev-
eral of the ingredients in ZB11 are known in Tibetan Med-
icine to prevent the most common side effects that typically
result from administration of prostaglandins, and were seen
at lower rates with ZB11 than with misoprostol in the Miller
et al. [25] trial. For example, cong zhi is used to prevent
and/or treat gastrointestinal side effects; ma nu prevents
fever, sdig srin prevents cramping, and a ru is generally be-
lieved to increase body energy and prevent a host of side-
effects [33, 34, 37]. It may be that the lower side effect profile
of ZB11 is due to these balancing effects although this has not
yet been critically analyzed.
Historical and anecdotal evidence for ZB11 and its in-
gredients’ clinical utility provides further support for ZB11’s
potential efficacy. What is especially interesting to note is
8 Evidence-Based Complementary and Alternative Medicine
that some of ZB11’s ingredients are used for similar purposes
across very different healing traditions. In African herbal
medicine, bul tog (calcium bicarbonate) is a well-known lax-
ative [40], while in Western Uganda, Sga skya, (Zingiber
officinale rose) is used to induce contractions [22]. Ol mo’se
(Himalayan mayapple) is used in traditional Chinese medi-
cine as a strong uterine stijmulant [26]. Rhubarb derivatives,
such as lcum rtsa, also appear in systems as diverse as tra-
ditional Chinese and Aryuvedic medicine to treat hemor-
rhage [21, 42]. The use of similar ingredients to augment
labor and cause uterine contractions in diverse traditional
medical practices lends support to the probability of an
uterotonic effect. While one explanation may be that these
healing traditions stem from similar ancestry and heritage,
the persistence of these compounds still suggests that they
have been found in practice to be effective by healers over
many generations. Evaluation of these compounds and
others within traditional medicine has the potential to iden-
tify culturally relevant, effective regimens that may prevent
morbidity and mortality from obstetric hemorrhage.
A limitation of our study was that we only looked at three
databases, none of which were Chinese (such as Chinese
National Knowledge Infrastructure and Wan Fang) due to
language barriers). We were also only able to review papers
that were written in or translated to English. Thus, studies
may be missing from our analysis. Moving forward, we rec-
ommend that the database sources be broadened, and that
additional Tibetan healers be consulted for their personal
opinions on and experience with ZB11.
5. Conclusions
Progress in Western medicine has often been the result of
accidental discovery, creating synthetic versions of naturally
occurring plant and animal substances, or adaptations of a
traditional medical system’s preparations. Examples include
the uterotonic ergometrine’s derivation from the fungus
Claviceps purpurea, and the use of the ancient Chinese
Traditional medication, Qinghao (Artemisia annua) for the
modern treatment of malaria. The findings of this ZB11
review suggest potential for both allopathic and continued
traditional use of ZB11 as an uterotonic, with further
research warranted to understand the underlying mecha-
nisms of action and synergy between ingredients.
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